Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MLYCD | O95822 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954477 | 0.90 | HPGD (0.57) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL14452241 | 0.84 | L3MBTL1 (0.71) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL13212973 | 0.84 | TDP1 (0.73) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL28851995 | 0.83 | POLB (0.71) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL31396762 | 0.83 | POLB (0.71) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL14520778 | 0.82 | ALDH1A1 (0.63) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL11089749 | 0.81 | HPGD (0.68) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL29286759 | 0.80 | HPGD (1.00) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL4491643 | 0.79 | TDP1 (0.75) | HPGDMAPTTSHRNPC1TP53 | |
| SCHEMBL1490952 | 0.79 | HPGD (0.76) | HPGDMAPTTSHRNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101084235-A | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS INC (US) | 2007-12-05 | — | — | CN | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | disclosed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | BROWN TRUMAN R | 2006-04-27 | — | — | US | disclosed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5476849-A | Inhibiting advanced glycosylation and/or crosslinking of target protein | THE ROCKEFELLER UNIVERSITY (US) | 1995-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | HPGD 1663/4885MAPT 677/4885TSHR 4155/4885 |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | ALDOA, FBP1, GYS2 | HPGD 20/4885MAPT 4399/4885TSHR 4770/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | HPGD 854/4885MAPT 3453/4885TSHR 4805/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | HPGD 127/4885MAPT 2715/4885TSHR 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.